[18F]Fluorodeoxyglucose PET for Interventional Oncology in Liver Malignancy

• Published in: PET clinics Vol. 9; no. 4; p. 469
• Main Authors: Samim, Morsal, El-Haddad, Ghassan E, Molenaar, Izaak Quintes, Prevoo, Warner, van den Bosch, Maurice A A J, Alavi, Abass, Lam, Marnix G E H
• Format: Journal Article
• Language: English
• Published: United States 01.10.2014
• Subjects: Fluorodeoxyglucose F18; Humans; Liver Neoplasms - diagnostic imaging; Liver Neoplasms - pathology; Liver Neoplasms - therapy; Multimodal Imaging; Neoplasm Recurrence, Local - diagnostic imaging; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; FDG-PET; Interventional oncology; Staging; Imaging; Liver; Radiofrequency ablation; Radioembolization; Chemoembolization
• DOI: 10.1016/j.cpet.2014.07.004

[(18)F]Fluorodeoxyglucose (FDG) PET is a functional imaging tool that provides metabolic information, which has the potential to detect a lesion before it becomes anatomically apparent. This ability constitutes a strong argument for using FDG-PET/computed tomography (CT) in the management of oncology patients. Many studies have investigated the accuracy of FDG-PET or FDG-PET/CT for these purposes, but with small sample sizes based on retrospective cohorts. This article provides an overview of the role of FDG-PET or FDG-PET/CT in patients with liver malignancies treated by means of surgical resection, ablative therapy, chemoembolization, radioembolization, and brachytherapy, all being liver-directed oncologic interventions.